Paradigm Biocapital Advisors’s Disc Medicine IRON Stock Holding History

Paradigm Biocapital Advisors’s Portfolio IRON Stock Details IRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-247,716	Closed	-$16.4M	–	38
2025 Q3	$16.4M	Sell	247,716 -963,255	-80%	-$57.3M	0.47%	34
2025 Q2	$64.1M	Hold	1,210,971	–	–	2.74%	12
2025 Q1	$60.1M	Sell	1,210,971 -286,749	-19%	-$15.9M	2.75%	11
2024 Q4	$95M	Hold	1,497,720	–	–	3.3%	12
2024 Q3	$73.6M	Sell	1,497,720 -1,206,998	-45%	-$56.7M	2.49%	11
2024 Q2	$122M	Buy	2,704,718 +314,816	+13%	+$10.7M	4.67%	6
2024 Q1	$149M	Buy	2,389,902 +4,045	+0.2%	+$262K	5.24%	4
2023 Q4	$138M	Buy	2,385,857 +1,113,578	+88%	+$57M	6.45%	4
2023 Q3	$59.8M	Buy	+1,272,279	New	+$63.6M	4.06%	11

Other funds holding IRON

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paradigm Biocapital Advisors's IRON Position: Q4 2025 in Review

Paradigm Biocapital Advisors sold out of Disc Medicine (IRON) in Q4 2025, closing a stake of 247,716 shares — an estimated $16.4M sold.

Paradigm Biocapital Advisors first reported a position in IRON in Q3 2023 and held it in 9 quarters. The position peaked at $149M in Q1 2024. 196 funds tracked by Wall St. Rank hold IRON as of Q4 2025.

Paradigm Biocapital Advisors reported no remaining Disc Medicine position as of Q4 2025 after selling out during the quarter.
Paradigm Biocapital Advisors sold 247,716 Disc Medicine shares in Q4 2025, an estimated $16.4M.
Paradigm Biocapital Advisors first reported a position in Disc Medicine in Q3 2023 and held it in 9 quarters.
Paradigm Biocapital Advisors's Disc Medicine position peaked at $149M in Q1 2024.
196 funds tracked by Wall St. Rank held Disc Medicine as of Q4 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.